Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-14.47M |
| Operating Margin | 0.00% |
| Return on Equity | -465.00% |
| Return on Assets | -193.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.95 |
| Price-to-Book | 2.89 |
| Price-to-Sales (TTM) | 1320.06 |
| EV/Revenue | 68.28 |
| EV/EBITDA | -0.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.75M |
| Float | $2.48M |
| % Insiders | 13.69% |
| % Institutions | 10.31% |
Volatility is currently expanding